Back to Search Start Over

Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model.

Authors :
Trincavelli ML
Cuboni S
Catena Dell'osso M
Maggio R
Klotz KN
Novi F
Panighini A
Daniele S
Martini C
Source :
Purinergic signalling [Purinergic Signal] 2010 Dec; Vol. 6 (4), pp. 373-81. Date of Electronic Publication: 2010 Oct 12.
Publication Year :
2010

Abstract

Unlabelled: A(2A) adenosine receptors are considered an excellent target for drug development in several neurological and psychiatric disorders. It is noteworthy that the responses evoked by A(2A) adenosine receptors are regulated by D(2) dopamine receptor ligands. These two receptors are co-expressed at the level of the basal ganglia and interact to form functional heterodimers. In this context, possible changes in A(2A) adenosine receptor functional responses caused by the chronic blockade/activation of D(2) dopamine receptors should be considered to optimise the therapeutic effectiveness of dopaminergic agents and to reduce any possible side effects. In the present paper, we investigated the regulation of A(2A) adenosine receptors induced by antipsychotic drugs, commonly acting as D(2) dopamine receptor antagonists, in a cellular model co-expressing both A(2A) and D(2) receptors. Our data suggest that the treatment of cells with the classical antipsychotic haloperidol increased both the affinity and responsiveness of the A(2A) receptor and also affected the degree of A(2A)-D(2) receptor heterodimerisation. In contrast, an atypical antipsychotic, clozapine, had no effect on A(2A) adenosine receptor parameters, suggesting that the two classes of drugs have different effects on adenosine-dopamine receptor interaction. Modifications to A(2A) adenosine receptors may play a significant role in determining cerebral adenosine effects during the chronic administration of antipsychotics in psychiatric diseases and may account for the efficacy of A(2A) adenosine receptor ligands in pathologies associated with dopaminergic system dysfunction.<br />Electronic Supplementary Material: The online version of this article (doi:10.1007/s11302-010-9201-z) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
1573-9546
Volume :
6
Issue :
4
Database :
MEDLINE
Journal :
Purinergic signalling
Publication Type :
Academic Journal
Accession number :
21437008
Full Text :
https://doi.org/10.1007/s11302-010-9201-z